Efficacy of outpatient treatment of alcohol use disorder

Efficacy and safety of outpatient alcohol treatment among people with alcohol use disorder referring to INCAS psychiatric clinic

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170702034844N3

Enrollment

Registered

2018-02-16

Start date

2018-04-21

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol use disorder. A cluster of behavioural, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences

Interventions

All patient who meet study eligibility criteria will receive outpatient fixed-schedule alcohol withdrawal treatment with benzodiazepines (diazepam) for 1 to 3 weeks according to national alcohol treat

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age: 18 to 65 years old Diagnosis of alcohol use disorder based on DSM-5 Providing informed written consent

Exclusion criteria

Exclusion criteria: Severe co-morbid psychiatric disorder including psychosis or suicide Inappropriate for outpatient treatment due to lack of family support, history of delirium tremens (DT) or seizures during previous alcohol withdrawal attempts Inappropriate for outpatient treatment due to severe alcohol dependence defined by score over 30 in SADQ test

Design outcomes

Primary

Measure	Time frame
Treatment retention. Timepoint: Weekly for 12 weeks. Method of measurement: Participation in weekly individual psychotherapy session.	—

Secondary

Measure	Time frame
Alcohol use disorders screening. Timepoint: Baseline and weeks 4 and 12. Method of measurement: Alcohol Use Disorder Identification Test (AUDIT).;Severity of alcohol dependence. Timepoint: Baseline and weeks 4 and 12. Method of measurement: Severity of Alcohol Dependence Questionnaire (SADQ).;Alcohol addiction severity. Timepoint: Baseline and week 12. Method of measurement: Alcohol section of Addiction Severity Index (ASI).;Aspartate Aminotransferase (AST). Timepoint: Baseline and weeks 4 and 12. Method of measurement: Blood test.;Alanine Aminotransferase (ALT). Timepoint: Baseline and weeks 4 and 12. Method of measurement: Blood test.;Gamma-Glutamyl Transferase (GGT). Timepoint: Baseline and weeks 4 and 12. Method of measurement: Blood test.	—

Measure

Time frame

Alcohol use disorders screening. Timepoint: Baseline and weeks 4 and 12. Method of measurement: Alcohol Use Disorder Identification Test (AUDIT).;Severity of alcohol dependence. Timepoint: Baseline and weeks 4 and 12. Method of measurement: Severity of Alcohol Dependence Questionnaire (SADQ).;Alcohol addiction severity. Timepoint: Baseline and week 12. Method of measurement: Alcohol section of Addiction Severity Index (ASI).;Aspartate Aminotransferase (AST). Timepoint: Baseline and weeks 4 and 12. Method of measurement: Blood test.;Alanine Aminotransferase (ALT). Timepoint: Baseline and weeks 4 and 12. Method of measurement: Blood test.;Gamma-Glutamyl Transferase (GGT). Timepoint: Baseline and weeks 4 and 12. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Noroozi

Tehran University of Medical Sciences

a_r_noroozi@yahoo.com+98 21 5541 5225

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026